Floatz logo

Nxy-059

Ischemic Attack, Transient

AstraZenecaPhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Ischemic Attack, Transient cohort.

Asset / SponsorPhaseRating
Plavix
Sichuan Provincial People's Hospital
Phase 4BBB
Acetylsalicylic Acid
Sichuan Provincial People's Hospital
Phase 4BBB
Ticagrelor
Mazandaran University of Medical Sciences
Phase 3BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Rivaroxaban
General Hospital of Shenyang Military Region
Phase 4BBB

View all 45 →

Same molecule, other indications

Nxy-059 is also rated in:

stroke disorderDormant
BB
Indicative ·
68 / 100
View asset →
intracerebral hemorrhageDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →